Skip to main content

MoneyWorks4Me

Hikal - Quaterly Results

04 Nov 2026 Evaluate
The sales for the September 2026 quarter moved up 36.33% to Rs. 4342.00 millions as compared to Rs. 3185.00 millions during the corresponding quarter last year.The Net Loss for the quarter ended September 2026 is Rs. -62.00 millions as compared to Net Loss of Rs. -347.00 millions of corresponding quarter ended September 2025Operating profit for the quarter ended September 2026 rose to 465.00 millions as compared to 93.00 millions of corresponding quarter ended September 2025.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202609 202509 % Var 202609 202509 % Var 202603 202503 % Var
Sales 4342.00 3185.00 36.33 8370.00 6989.00 19.76 17126.00 18598.00 -7.91
Other Income 17.00 19.00 -10.53 35.00 29.00 20.69 123.00 50.00 146.00
PBIDT 465.00 93.00 400.00 852.00 351.00 142.74 2328.00 3335.00 -30.19
Interest 134.00 149.00 -10.07 283.00 320.00 -11.56 621.00 752.00 -17.42
PBDT 331.00 -56.00 -691.07 658.00 31.00 2022.58 856.00 2583.00 -66.86
Depreciation 417.00 412.00 1.21 844.00 806.00 4.71 1638.00 1344.00 21.88
PBT -86.00 -468.00 -81.62 -186.00 -775.00 -76.00 -782.00 1239.00 -163.12
TAX -24.00 -121.00 -80.17 -49.00 -201.00 -75.62 -295.00 330.00 -189.39
Deferred Tax -24.00 -121.00 -80.17 -49.00 -201.00 -75.62 -275.00 30.00 -1016.67
PAT -62.00 -347.00 -82.13 -137.00 -574.00 -76.13 -487.00 909.00 -153.58
Equity 247.00 247.00 0.00 247.00 247.00 0.00 247.00 247.00 0.00
PBIDTM(%) 10.71 2.92 266.77 10.18 5.02 102.68 13.59 17.93 -24.19
Peers
Company Name CMP
Sun Pharma. Inds. 1909.75
Dr. Reddys Labs. 1379.00
Cipla 1406.00
Lupin 2011.60
Zydus Lifesciences 1210.60
View more..